A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
In: BMC Cancer, Jg. 12 (2012), Heft 1, S. 108-113
Online
academicJournal
Zugriff:
Titel: |
A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
|
---|---|
Link: | |
Zeitschrift: | BMC Cancer, Jg. 12 (2012), Heft 1, S. 108-113 |
Veröffentlichung: | 2012 |
Medientyp: | academicJournal |
ISSN: | 1471-2407 (print) |
DOI: | 10.1186/1471-2407-12-108 |
Sonstiges: |
|